CL2022001743A1 - Dosis de gamma-hidroxibutirato (ghb) - Google Patents

Dosis de gamma-hidroxibutirato (ghb)

Info

Publication number
CL2022001743A1
CL2022001743A1 CL2022001743A CL2022001743A CL2022001743A1 CL 2022001743 A1 CL2022001743 A1 CL 2022001743A1 CL 2022001743 A CL2022001743 A CL 2022001743A CL 2022001743 A CL2022001743 A CL 2022001743A CL 2022001743 A1 CL2022001743 A1 CL 2022001743A1
Authority
CL
Chile
Prior art keywords
ghb
hydroxybutyrate
gamma
dosage
narcolepsy
Prior art date
Application number
CL2022001743A
Other languages
English (en)
Inventor
Skobieranda Franck
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of CL2022001743A1 publication Critical patent/CL2022001743A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

En el presente documento se proporcionan métodos para administrar formulaciones de GHB para el tratamiento de la narcolepsia y otras afecciones.
CL2022001743A 2019-12-24 2022-06-24 Dosis de gamma-hidroxibutirato (ghb) CL2022001743A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US202063052676P 2020-07-16 2020-07-16

Publications (1)

Publication Number Publication Date
CL2022001743A1 true CL2022001743A1 (es) 2023-02-10

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001743A CL2022001743A1 (es) 2019-12-24 2022-06-24 Dosis de gamma-hidroxibutirato (ghb)

Country Status (14)

Country Link
US (2) US20210186907A1 (es)
EP (1) EP4081204A1 (es)
JP (1) JP2023508975A (es)
KR (1) KR20220119429A (es)
CN (1) CN115209885A (es)
AU (1) AU2020414694A1 (es)
BR (1) BR112022012594A2 (es)
CA (1) CA3162974A1 (es)
CL (1) CL2022001743A1 (es)
CO (1) CO2022010330A2 (es)
IL (1) IL294176A (es)
MX (1) MX2022007968A (es)
TW (1) TW202135790A (es)
WO (1) WO2021133778A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69907508T2 (de) 1998-12-23 2003-11-20 Orphan Medical Inc Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
EP1325014B1 (en) 2000-09-22 2012-05-23 JPI Commercial, LLC Gamma-hydroxybutyrate compositions containing carbohydrate carriers
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
EP4081204A1 (en) 2022-11-02
CN115209885A (zh) 2022-10-18
MX2022007968A (es) 2022-09-02
US20210361601A1 (en) 2021-11-25
US20210186907A1 (en) 2021-06-24
BR112022012594A2 (pt) 2022-09-06
TW202135790A (zh) 2021-10-01
IL294176A (en) 2022-08-01
WO2021133778A1 (en) 2021-07-01
AU2020414694A1 (en) 2022-08-18
KR20220119429A (ko) 2022-08-29
CO2022010330A2 (es) 2022-10-21
CA3162974A1 (en) 2021-07-01
JP2023508975A (ja) 2023-03-06

Similar Documents

Publication Publication Date Title
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
EA202191519A1 (ru) Модуляторы trex1
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CO2022000481A2 (es) Inhibidores de enzimas
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2022000270A2 (es) Inhibidores de enzimas
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CO2022000266A2 (es) Inhibidores de enzimas
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CO2022014499A2 (es) Moduladores de nlrp3
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)